2026-04-29T12:24:02Zhttps://repisalud.isciii.es/rest/oai/requestoai:repisalud.isciii.es:20.500.12105/179362024-09-21T22:34:52Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16927
Repisalud
author
Comi, Giancarlo
author
Alroughani, Raed
author
Boster, Aaron L
author
Bass, Ann D
author
Berkovich, Regina
author
Fernández, Óscar
author
Kim, Ho Jin
author
Limmroth, Volker
author
Lycke, Jan
author
Macdonell, Richard Al
author
Sharrack, Basil
author
Singer, Barry A
author
Vermersch, Patrick
author
Wiendl, Heinz
author
Ziemssen, Tjalf
author
Jacobs, Alan
author
Daizadeh, Nadia
author
Rodriguez, Claudio E
author
Traboulsee, Anthony
author
CARE-MS I, CARE-MS II, CAMMS03409, and TOPAZ Investigators
2024-02-10T20:02:33Z
2024-02-10T20:02:33Z
2019-11-25
10.1177/1352458519888610
1477-0970
Multiple sclerosis (Houndmills, Basingstoke, England)
http://hdl.handle.net/10668/14739
31762387
http://hdl.handle.net/20.500.12105/17936
Alemtuzumab is given as two annual courses. Patients with continued disease activity may receive as-needed additional courses. To evaluate efficacy and safety of additional alemtuzumab courses in the CARE-MS (Comparison of Alemtuzumab and Rebif® Efficacy in Multiple Sclerosis) studies and their extensions. Subgroups were based on the number of additional alemtuzumab courses received. Exclusion criteria: other disease-modifying therapy (DMT); In the additional-courses groups, Courses 3 and 4 reduced annualized relapse rate (12 months before: 0.73 and 0.74, respectively; 12 months after: 0.07 and 0.08). For 36 months after Courses 3 and 4, 89% and 92% of patients were free of 6-month confirmed disability worsening, respectively, with 20% and 26% achieving 6-month confirmed disability improvement. Freedom from magnetic resonance imaging (MRI) disease activity increased after Courses 3 and 4 (12 months before: 43% and 53%, respectively; 12 months after: 73% and 74%). Safety was similar across groups; serious events occurred irrespective of the number of courses. Additional alemtuzumab courses significantly improved outcomes, without increased safety risks, in CARE-MS patients with continued disease activity after Course 2. How this compares to outcomes if treatment is switched to another DMT instead remains unknown.
eng
Alemtuzumab
Efficacy
Multiple sclerosis
Relapse
Retreatment
safety
Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies.
research article